SubHero Banner

Brineura (cerliponase alfa) – New orphan drug approval

April 27, 2017 – The FDA announced the approval of BioMarin’s Brineura (cerliponase alfa), to slow loss of ambulation in symptomatic pediatric patients ≥ 3 years of age with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Download PDF